Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Gossamer Bio (GOSS) EBITDA Margin: 2022-2025

Historic EBITDA Margin for Gossamer Bio (GOSS) over the last 4 years, with Sep 2025 value amounting to -362.87%.

  • Gossamer Bio's EBITDA Margin fell 1987.00% to -362.87% in Q3 2025 from the same period last year, while for Sep 2025 it was -793.20%, marking a year-over-year decrease of 71917.00%. This contributed to the annual value of -60.63% for FY2024, which is 138986.00% down from last year.
  • Per Gossamer Bio's latest filing, its EBITDA Margin stood at -362.87% for Q3 2025, which was up 1.99% from -370.24% recorded in Q2 2025.
  • Over the past 5 years, Gossamer Bio's EBITDA Margin peaked at 1,710.33% during Q3 2022, and registered a low of -390.85% during Q1 2025.
  • Its 3-year average for EBITDA Margin is 496.04%, with a median of 202.50% in 2024.
  • Data for Gossamer Bio's EBITDA Margin shows a maximum YoY plummeted of 173,971bps (in 2025) over the last 5 years.
  • Gossamer Bio's EBITDA Margin (Quarterly) stood at 1,612.76% in 2022, then plummeted by 13,452bps to 1,478.23% in 2023, then tumbled by 127,574bps to 202.50% in 2024, then plummeted by 1,987bps to -362.87% in 2025.
  • Its EBITDA Margin was -362.87% in Q3 2025, compared to -370.24% in Q2 2025 and -390.85% in Q1 2025.